Vitiligo

Ruxolitinib is the first and only approved treatment for repigmentation in the European Union.

Despite a lack of FDA-approved treatments and management options for patients with vitiligo, both dermatologists and patients alike have options for care.

Researchers said laser and intense pulse light-induced vitiligo lacks consensus in prevention and safety measures.

According to new research, vitamin D and serum brain-derived neurotrophic factors may exacerbate depression in some dermatologic patients.

The investigational oral JAK1 inhibitor showed promising results for vitiligo patients.

By week 24 of the phase 3 study, a quarter of participants felt their vitiligo had improved.

Following 2 phase 3 trials, the European Medicines Agency Committee for Medicinal Products for Human Use gives positive opinion on the use of ruxolitinib cream as a treatment for facial-involved non-segmental vitiligo.

Research has begun to explore natural compounds that address the oxidative stress, autoimmunity, and altered melanogenesis that drive vitiligo pathogenesis.

Latin America presents a patchwork of challenges and opportunities in vitiligo management according to a review published in the Journal of Dermatological Treatment.

Clinicians should strive to address the unique medical and aesthetic challenges seen in vitiligo.

PDT has an advantage in that it can combine easily with other therapies, thereby increasing its effectiveness rates.

Several dietary approaches have been proposed to play a role in the pathogenesis, management, and/or therapy of diseases such as vitiligo.

Seemal Desai, MD, shares highlights from his session at Winter Clinical Hawaii.

Two specialists discuss prevalence, patient communication, and exciting new therapy.

The melanocytes attacked by the autoimmune disease are present in the eyes and ears, not just the skin, so vitiligo can adversely affect vision and hearing.

Because vitiligo affects appearance, people with vitiligo are disproportionately affected by psychiatric conditions, including depression.

Phototherapy can serve an important role in the therapeutic armamentarium of vitiligo as it is safe, cost-effective, and can treat patients with large areas of disease.

Vitiligo can have a profound effect on mental health and quality of life.

Israeli researchers find more than five fold risk of developing systemic sclerosis among people with vitiligo.

A recent systematic review on surgical therapies for vitiligo examined surgical therapies such as punch grafting, suction blister epidermal grafting, and cellular grafting techniques

Vitiligo, an autoimmune skin condition that causes depigmentation, can have a large effect on a patient’s quality of life and psychosocial well-being.

At the 2022 Fall Clinical Dermatology Conference, 5 practitioners share their best tips for treating their patients

Improvement of vitiligo repigmentation in patients can result in higher Vitiligo Noticeability Scale values when assessed from patient-reported outcome measures (PROMs) versus traditional investigator-assessed studies.

The search for the causes of vitiligo continues. The findings in this study stand in contrast to another one conducted in eastern China that showed a high percentage of children with vitiligo had thyroid abnormalities.

A recent review article lists six other JAK inhibitors that might be used as treatments for vitiligo in addition to ruxolitinib, the active ingredient in recently approved Opzelura.

A case study reviewed an 11-year-old male for loss of pigmentation of the right side of his back and right arm.

At the Skin of Color Update 2022 meeting, Pearl Grimes, MD, shares her thoughts on the recent approval of ruxolitinib cream.

Improvement of vitiligo repigmentation in patients can result in higher Vitiligo Noticeability Scale values when assessed from patient-reported outcome measures (PROMs) versus traditional investigator-assessed studies.

Pigmentary disorders of the skin can be the cause of significant psychological distress in affected patients.

Hiring investigators of color, educating and building trust with potential participants, and addressing funding can make clinical trials more diverse.